Key result
Sacubitril/valsartan research in CKD expands rapidly to ~250 publications, led by China and the US.
This bibliometric analysis maps the rapid growth of research on sacubitril/valsartan in chronic kidney disease from 2013 to 2025, highlighting a shift toward cardiorenal outcomes and SGLT2 inhibitor combination therapy while identifying persistent evidence gaps in dialysis dosing and long-term ESRD safety.
Answers are grounded in this paper and cite their sources.
Rapid publication growth on sacubitril/valsartan in CKD signals rising interest; leaves open gaps in dialysis dosing and long-term ESRD safety.
This bibliometric analysis delineates the evolving research landscape of sacubitril/valsartan in CKD from 2013 to 2025, highlighting sustained growth, key contributors, and emerging research themes. The findings underscore increasing attention to cardiorenal applications, precision medicine, and combination therapies, while also identifying persistent gaps related to long-term safety, dialysis dosing, and renoprotective mechanisms. These insights provide a structured reference to inform future clinical and translational research in CKD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Chronic kidney disease (n=254). Sacubitril/valsartan was evaluated on Bibliometric publication trends, collaboration networks, co-citation clusters, and keyword co-occurrence in sacubitril/valsartan research for CKD. Sacubitril/valsartan research in chronic kidney disease grew steadily to 254 publications between 2013 and 2025, led by China and the United States with 73 articles each.
Synapse has enriched 10 related papers. Consider them for comparative context: